Sagimet Biosciences Inc [SGMT] stock is trading at $5.73, up 30.52%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SGMT shares have gain 13.47% over the last week, with a monthly amount glided 10.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sagimet Biosciences Inc [NASDAQ: SGMT] stock has seen the most recent analyst activity on December 06, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $30. Previously, UBS started tracking the stock with Buy rating on November 12, 2024, and set its price target to $12. On June 28, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $6 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $32 on May 02, 2024. Leerink Partners initiated its recommendation with a Outperform and recommended $26 as its price target on March 25, 2024. In a note dated August 08, 2023, Piper Sandler initiated an Overweight rating and provided a target price of $67 on this stock.
Sagimet Biosciences Inc [SGMT] stock has fluctuated between $2.39 and $20.71 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Sagimet Biosciences Inc [NASDAQ: SGMT] shares were valued at $5.73 at the most recent close of the market. An investor can expect a potential return of 4.71% based on the average SGMT price forecast.
Analyzing the SGMT fundamentals
Sagimet Biosciences Inc [NASDAQ:SGMT] reported sales of 0.00M for the trailing twelve months, which represents a drop of -100.00%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.24 and Total Capital is -0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.03 points at the first support level, and at 4.34 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.32, and for the 2nd resistance point, it is at 6.92.
Ratios To Look Out For
For context, Sagimet Biosciences Inc’s Current Ratio is 38.34. Further, the Quick Ratio stands at 38.34, while the Cash Ratio is 18.82.
Transactions by insiders
Recent insider trading involved Kemble George, Executive Chairman, that happened on Jul 23 ’24 when 23625.0 shares were sold. Chief Medical Officer, Martins Eduardo Bruno completed a deal on Jul 19 ’24 to sell 8357.0 shares. Meanwhile, General Counsel and CCO Rozek Elizabeth sold 10914.0 shares on Jul 19 ’24.
